Recently, the "China ESG (Corporate Social Responsibility) Release" event, jointly launched by the CCTV Finance Program Center, the State-owned Assets Supervision and Administration Commission of the State Council, the All-China Federation of Industry and Commerce, the Institute of Economics of the Chinese Academy of Social Sciences, and the China Enterprise Reform and Development Society, was officially held in Beijing. During the event, the "Annual ESG Action Report" was officially released, and the "China ESG Listed Companies Pioneer 100" list was announced. With its high-quality ESG management and excellent ESG performance, Sino Biopharm stood out from 855 participating listed companies to be successfully included in the list. Its ESG index ranked 57th on the list, receiving an evaluation of "leading level in ESG development among listed companies".

The "China ESG Listed Companies Pioneer 100" list used a sample pool of 6,405 Chinese listed companies from both A-shares and H-shares. Based on factors such as market capitalization, ESG report publication status, listed company influence, and ESG activity, 855 listed companies were comprehensively selected as evaluation subjects. Ultimately, the 100 listed companies with leading ESG evaluation results were selected for the "Pioneer 100" list. This inclusion in the "Pioneer 100" list represents the authoritative affirmation of Sino Biopharm's effectiveness in the field of ESG governance and practice by relevant institutional departments.

As a leading innovation and R&D-driven pharmaceutical group in China, Sino Biopharm has always upheld the corporate mission of "Improving the quality and protecting the dignity of human life". With the vision of "To be a leading global pharmaceutical company through delivering innovative therapies for patients", it continues to cultivate its strengths in product technology and holds a leading position in the four core therapeutic fields of oncology, hepatology, respiratory, and surgery/analgesic.

While seeking health and well-being for more patients and enabling more diseases to be treated, Sino Biopharm actively practices ESG governance and undertakes corporate social responsibility. It is continuously committed to promoting the harmonious development of the company, employees, society, and the environment, creating long-term value for itself and partners from all sectors. In the future, Sino Biopharm will continue to deepen its efforts in the ESG field, practice the ESG concept, enhance its ESG governance level, and actively carry out ESG practices, demonstrating corporate responsibility.